Menu Search
Equities

Catalyst Pharmaceuticals Inc

CPRX:NAQ

Catalyst Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.67
  • Today's Change-1.29 / -5.87%
  • Shares traded1.25m
  • 1 Year change+27.20%
  • Beta0.8419
Data delayed at least 15 minutes, as of Mar 10 2025 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Catalyst Pharmaceuticals Inc grew revenues 23.49% from 398.20m to 491.73m while net income improved 129.50% from 71.41m to 163.89m.
Gross margin86.00%
Net profit margin33.33%
Operating margin39.68%
Return on assets24.80%
Return on equity29.38%
Return on investment29.14%
More ▼

Cash flow in USDView more

In 2024, Catalyst Pharmaceuticals Inc increased its cash reserves by 276.03%, or 379.92m. The company earned 239.81m from its operations for a Cash Flow Margin of 48.77%. In addition the company generated 140.67m cash from financing while 556.00k was spent on investing.
Cash flow per share1.61
Price/Cash flow per share13.23
Book value per share6.02
Tangible book value per share4.72
More ▼

Balance sheet in USDView more

Catalyst Pharmaceuticals Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 517.55m.
Current ratio5.17
Quick ratio5.01
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 108.95%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)34.26
EPS (TTM) vs
TTM 1 year ago		114.86
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.